Company Overview and News
Greetings, and welcome to the TIER REIT Second Quarter 2018 Earnings Call. [Operator Instructions]. As a reminder, this conference is being recorded.
Tier Reit (TIER - Free Report) just came out with quarterly earnings of $0.40 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.41 per share a year ago. These figures are adjusted for non-recurring items.
KRO TIER CIVI SBOW
Chicago, IL – June 8, 2018 – Today, Zacks Investment Ideas feature highlights Features: Expedia Group Inc (EXPE - Free Report) , TripAdvisor Inc (TRIP - Free Report) and Booking Holdings (BKNG - Free Report) .
TTWO FIX TRIP LB EXPE BKNG UFPI TIER MU PATK PCLN PETS IO
Chicago, IL – June 7, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Aptiv PLC (APTV - Free Report) , Spirax-Sarco Engineering plc (SPXSF - Free Report) , NMC Health Plc (NMHLY - Free Report) , Safestore Holdings plc (SFSHF - Free Report) and TT Electronics plc (TTGPF - Free Report) .
SFSHF TTG NMC ALGN BURL NMHLY FIX UFPI SPX TTGPF TIER PATK LULU PETS IO APTV
Chicago, IL – June 7, 2018 – Today, Zacks Equity Research discusses the Industry: E-commerce, including Alibaba (BABA - Free Report) , Amazon (AMZN - Free Report) , Walmart (WMT - Free Report) and Google (GOOGL - Free Report) .
ALGN UFPI BURL GOOGL TIER FIX PATK LULU PETS IO
Chicago, IL – June 7, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Medifast, Inc. (MED - Free Report) , The Chefs' Warehouse, Inc. (CHEF - Free Report) and Conagra Brands, Inc. (CAG - Free Report) .
ALGN GIS BURL FIX MDLZ CHEF UFPI TIER PATK MED LULU PETS IO
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to TIER / Tier Reit Inc. on message board site Silicon Investor.
as of ET